FIELD NOTE / SPECIFIC APPROVAL
Tesamorelin
This page separates tesamorelin's specific approved use from the wider claims you may see online. FDA, the U.S. drug regulator, has approved a specific tesamorelin product. That does not make every product with the same ingredient approved, or establish a general role in weight loss or training.
NXT LVL may earn money when readers become Promise patients.
Promise prescribes now. A licensed U.S. provider reviews each request and decides whether to prescribe. Not everyone qualifies. Compounded medicines are made to order and are not FDA-approved.
U.S. patients only. Availability varies by state and by treatment. Promise does not offer care outside the U.S.
What the molecule is.
Tesamorelin is a lab-made version of growth-hormone-releasing hormone, the signal sent from the brain to the pituitary gland beneath it. It has an added chemical part that slows its breakdown. A peptide is a chain of amino acids, the parts that make up proteins.
It signals the pituitary to release growth hormone. That makes it a secretagogue, a substance that prompts hormone release. It is not growth hormone itself.
The approved use has a boundary.
An FDA-approved tesamorelin product is indicated for excess abdominal fat in adults with HIV who have lipodystrophy. Lipodystrophy means a change in where the body stores fat. HIV is the virus that affects the immune system.
The approved label says the medicine is not for weight loss. Its trials involved people with that specific medical condition. Their results do not establish what a healthy person seeking a body-composition change could expect. The long-term effect on the heart and blood vessels is unknown.
The finished product matters.
Compounded versions are not FDA-approved. Compounded means prepared to order rather than supplied as an approved finished product. A research-labeled product, or a blend with ipamorelin, is not the approved tesamorelin product.
Tesamorelin is legally classed as a biologic, a medicine in a category with separate federal rules. Those rules do not allow pharmacies to make their own copies through the usual compounding exemptions. The fact that an approved product exists is not permission to prepare a copy.
Promise lists these options for provider review. A licensed U.S. provider decides whether to prescribe. The listing does not change FDA status or the rules for the exact ingredient.
What a provider reviews.
The approved label calls for attention to blood sugar, cancer history and pituitary health. It also discusses IGF-1, a protein involved in growth whose level can change with growth hormone. These are medical questions, not details that a training goal can answer.
The label excludes use during pregnancy and with active cancer or certain pituitary problems. It describes possible swelling, joint pain, blood-sugar changes and allergic reactions. This guide explains why review matters; it cannot decide whether treatment fits an individual.
Put the pairing in context.
Source notes
Put the next step in licensed hands.
A Promise visit starts a request for review. A licensed U.S. provider decides whether to prescribe. Not everyone qualifies, and no particular treatment is promised.
NXT LVL may earn money when readers become Promise patients.
Promise prescribes these peptides now through licensed U.S. providers. A provider reviews every request and decides. Not everyone qualifies.
U.S. patients only. Availability varies by state and by treatment. Promise does not offer care outside the U.S.